Efficacy of Subconjunctivally Applied Everolimus- and Sirolimus-Pretreated MSCs in Preventing Diabetic Retinopathy
Translational Vision Science & Technology · 2025
DOI: 10.1167/tvst.14.9.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Ji Seung Jung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Veterinary Surgery and Ophthalmology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea. Hauptthemen laut MEDLINE: Everolimus, Diabetic Retinopathy, Sirolimus, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Diabetic retinopathy (DR) is a leading cause of vision impairment in diabetic patients. This study investigates the preventive effects of subconjunctivally applied mesenchymal stem cells (MSCs) pretreated with mammalian target of rapamycin (mTOR) inhibitors on DR.
Methods
Thirty-six male Sprague-Dawley rats were used, with diabetes induced by a single intraperitoneal injection of streptozotocin (STZ) at 55 mg/kg. Four groups were established: diabetic control, MSC-treated, everolimus-pretreated MSC-treated (MSC-E), and sirolimus-pretreated MSC-treated (MSC-S). Each treated group received subconjunctival injections of 1 × 106 MSCs in 30 µL phosphate-buffered saline at 3, 5, and 7 weeks post-STZ. Electroretinography (ERG) was performed at 2 and 8 weeks post-STZ. At 11 weeks, cataract formation, uveitis grading, and retinal histology were assessed. Results: mTOR inhibitor-pretreated MSCs significantly prevented the decline in retinal function compared to untreated MSCs and diabetic controls. Everolimus-pretreated MSCs tended to show higher ERG flicker amplitudes than sirolimus-pretreated MSCs, although the difference was not statistically significant. Histologically, both pretreated groups showed preserved thickness in the outer plexiform and nuclear layers, suggesting protection against retinal damage.
Conclusions
Subconjunctival application of MSCs pretreated with mTOR inhibitors may help prevent DR progression, with everolimus showing a potential advantage in preserving retinal function. Translational Relevance: These findings suggest that mTOR inhibitor-pretreated MSCs could be a viable therapeutic strategy for DR, warranting further clinical trials to confirm efficacy and safety in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Veterinary Surgery and Ophthalmology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea.
- Laboratory of Veterinary Physiology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea.
Zitieren
APA
Jung, J. S., Jo, H. Y., Hwang, J., Kim, D., Kwon, M., Yong, J., Yoon, H., Lee, H. J., & Park, K. M. (2025). Efficacy of Subconjunctivally Applied Everolimus- and Sirolimus-Pretreated MSCs in Preventing Diabetic Retinopathy. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.9.19
Vancouver
Jung JS, Jo HY, Hwang J, Kim D, Kwon M, Yong J, et al. Efficacy of Subconjunctivally Applied Everolimus- and Sirolimus-Pretreated MSCs in Preventing Diabetic Retinopathy. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.9.19
BibTeX
@article{Jung2025,
author = {Jung, Ji Seung and Jo, Hyo Youn and Hwang, Jiyi and Kim, Donghee and Kwon, Myeongjee and Yong, Jungyeon and Yoon, Haerin and Lee, Hyun Jik and Park, Kyung-Mee},
title = {Efficacy of Subconjunctivally Applied Everolimus- and Sirolimus-Pretreated MSCs in Preventing Diabetic Retinopathy},
journal = {Translational Vision Science & Technology},
year = {2025},
doi = {10.1167/tvst.14.9.19}
}
EUVIMED